Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 523Leukemia, Myeloid, Acute 500Neoplasms 382Carcinoma, Non-Small-Cell Lung 381Pancreatic Neoplasms 329Precursor Cell Lymphoblastic Leukemia-Lymphoma 319Multiple Myeloma 312Glioblastoma 312Melanoma 310Prostatic Neoplasms 293Leukemia 289Neoplasm Metastasis 285Brain Neoplasms 277Lymphoma 271Lung Neoplasms 270Recurrence 267Ovarian Neoplasms 247Colorectal Neoplasms 246Lymphoma, Non-Hodgkin 242Leukemia, Lymphocytic, Chronic, B-Cell 231Glioma 210Myelodysplastic Syndromes 208Lymphoma, Large B-Cell, Diffuse 187Carcinoma, Hepatocellular 173Lymphoma, Follicular 168Head and Neck Neoplasms 162Hodgkin Disease 160Lymphoma, Mantle-Cell 155Burkitt Lymphoma 154Sarcoma 150

Interventions

Secretin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Intraductal Papillary Mucinous Neoplasms × Clear all
NCT00621556 2009-01-29

Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas

Massachusetts General Hospital

Phase 1 Terminated
2 enrolled

Intraductal Papillary Mucinous Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡